Outpatient Administration of Bispecific Antibody Therapy for Hematologic Malignancies: A Practical Guide
JCO Oncology Practice · 2026
DOI: 10.1200/op-25-00652 ↗Kurz gefasst
Leitlinie in der Zeitschrift JCO Oncology Practice, 2026. Verfasst von Kian J Rahbari und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Vanderbilt University Medical Center, Nashville, TN. Hauptthemen laut MEDLINE: Antibodies, Bispecific, Antineoplastic Agents, Immunological, Hematologic Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 48 Literaturangaben.
Abstract (Originalsprache)
Bispecific antibodies (BsAbs) are currently used to treat hematologic malignancies by cross-linking cytotoxic T cells with tumor cells and thus stimulating cellular immunity. Hyperactivation of T cells leads to dysregulated cytokine release, which causes the chief toxicities of BsAbs, cytokine release syndrome (CRS) and immune effector cell–mediated neurotoxicity syndrome (ICANS). On the basis of clinical trial experiences, standard practice is to hospitalize patients for intensive monitoring during periods when the risk of CRS and ICANS is highest. A strategy to safely administer these medications outpatient would improve patient access and reduce health care–associated costs. The lessons learned from outpatient administration of chimeric antigen receptor T cell therapy (CAR-T) may be applied to BsAbs given overlapping toxicity profiles. Outpatient delivery of BsAbs is feasible but requires a specialized multidisciplinary team, a robust infrastructure with well-defined standard procedures, and significant patient support and education. Emerging clinical practices, including prophylactic anti-inflammatory therapy and modified dosing schedules, further facilitate safe outpatient administration.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine, Vanderbilt University Medical Center, Nashville, TN.
- Department of Internal Medicine, Texas Tech Health El Paso, El Paso, TX.
- Division of Hematology and Medical Oncology, Department of Internal Medicine, Vanderbilt University Medical Center, Nashville, TN.
ORCID-Profile: Kian J Rahbari, Reena V Jayani-Kosarzycki, Andrew Jallouk, Tae Kon Kim, Shakthi Bhaskar, Vivek G Patel, David Morgan, Bipin N Savani, Muhamed Baljevic, Olalekan Oluwole, Bhagirathbhai Dholaria
Zitieren
APA
Rahbari, K. J., Mijares, R. D. T., Kennedy, K., Mader, L., Sengsayadeth, S., Jayani-Kosarzycki, R. V., Jerkins, J., Jallouk, A., Kim, T. K., Bhaskar, S., Patel, V. G., Baer, B., Moseley, S., Morgan, D., Savani, B. N., Kassim, A., Baljevic, M., Oluwole, O., & Dholaria, B. (2026). Outpatient Administration of Bispecific Antibody Therapy for Hematologic Malignancies: A Practical Guide. JCO Oncology Practice. https://doi.org/10.1200/op-25-00652
Vancouver
Rahbari KJ, Mijares RDT, Kennedy K, Mader L, Sengsayadeth S, Jayani-Kosarzycki RV, et al. Outpatient Administration of Bispecific Antibody Therapy for Hematologic Malignancies: A Practical Guide. JCO Oncology Practice. 2026. doi:10.1200/op-25-00652
BibTeX
@article{Rahbari2026,
author = {Rahbari, Kian J and Mijares, Raul Del Toro and Kennedy, Kathryn and Mader, Leslie and Sengsayadeth, Salyka and Jayani-Kosarzycki, Reena V and Jerkins, James and Jallouk, Andrew and Kim, Tae Kon and Bhaskar, Shakthi and Patel, Vivek G and Baer, Brittney and Moseley, Sarah and Morgan, David and Savani, Bipin N and Kassim, Adetola and Baljevic, Muhamed and Oluwole, Olalekan and Dholaria, Bhagirathbhai},
title = {Outpatient Administration of Bispecific Antibody Therapy for Hematologic Malignancies: A Practical Guide},
journal = {JCO Oncology Practice},
year = {2026},
doi = {10.1200/op-25-00652}
}
EUVIMED